MedTrace Logo

Cadonilimab in Combination With Ramucirumab for the Treatment of Advanced Hepatocellular Carcinoma That Has Failed at Systemic Therapy

NCT05856864 · Status: UNKNOWN · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 30

Last updated 2024-04-15

No results posted yet for this study

Summary

To evaluate the efficacy Cadonilimab in combination with Ramucirumab for the treatment of advanced Hepatocellular Carcinoma that has failed at systemic therapy

Conditions

  • Advanced Hepatocellular Carcinoma That Has Failed at Systemic Therapy

Interventions

DRUG

Cadonilimab Injection

Cadonilimab Injection, 10mg/kg, intravenous drip ,q2w,

DRUG

Ramucirumab Injection

Ramucirumab Injection，8mg/kg, intravenous drip ,q2w,

Sponsors & Collaborators

  • Tianjin Medical University Cancer Institute and Hospital

    lead OTHER

Principal Investigators

  • Huikai Li, MD · Tianjin Cancer Hospital Airport Hospital

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-06-01
Primary Completion
2024-07-01
Completion
2025-05-01

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05856864 on ClinicalTrials.gov